Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around

Description

Summary

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

Official Title

An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Keywords

Psoriasis, Deucravacitinib, BMS-986165

Eligibility

You can join if…

Open to people ages 18 years and up

  • Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis
  • Women must not be pregnant, lactating, or breastfeeding

You CAN'T join if...

  • Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.
  • To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.

    Other protocol-defined inclusion/exclusion criteria apply

Locations

  • University of California San Diego Health Systems
    San Diego California 92122 United States
  • Local Institution - 0017
    Irvine California 92697 United States
  • Clinical Science Institute
    Santa Monica California 90404 United States
  • Local Institution - 0042
    Sherman Oaks California 91403 United States
  • Dermatology Research Associates - Los Angeles
    Los Angeles California 90045-3606 United States
  • First OC Dermatology & Belle-Aimee Skincare Clinic Fountain Valley
    Fountain Valley California 92708 United States
  • Local Institution - 0206
    Fresno California 93720 United States
  • Therapeutics Clinical Research
    San Diego California 92123 United States
  • University Dermatology Group
    San Diego California 92123 United States
  • Local Institution - 0236
    Los Angeles California 90057 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls
ID
NCT04036435
Phase
Phase 3 Psoriasis Research Study
Study Type
Interventional
Participants
About 1452 people participating
Last Updated